Thursday 16 October, 2025
Objectives: Nevirapine (NVP) is a non-nucleoside reverse-transcriptase inhibitor of human immunodeficiency virus (HIV) type 1. NVP can be coadministered safely…
Read morePoster: Drug/Disease Modelling - Infection
Evaluation of IRT-derived disease severity as a predictor of clinical success in critically ill patients with severe antibiotic resistant infections
Thursday 16 October, 2025
Introduction: The Sequential Organ Failure Assessment score (SOFA) is used to measure the severity of organ dysfunction and is widely…
Read moreA translational semi-mechanistic pharmacokinetic-pharmacodynamic framework to design animal studies: Application to linezolid and vancomycin
Thursday 16 October, 2025
Objectives: One of the aims of the COMBINE project, which is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme, is…
Read moreAssessing clinical outcomes of nosocomial pneumonia patients with a pharmacometric multistate model
Thursday 16 October, 2025
Objectives: In the field of antibiotics, pharmacometric methods are usually applied to preclinical data that mostly contains longitudinal information. However,…
Read moreThe FAIR approach: Utilising a modelling and simulation workflow leveraging multisource data to support preclinical development and clinical trials
Thursday 16 October, 2025
Background and Objectives: In this work, we outline how mathematical modelling can be utilised throughout the development of an inhaled…
Read moreQuantitative modelling of procalcitonin as a treatment response biomarker in sepsis
Thursday 16 October, 2025
Introduction: The use of host response biomarkers to guide antibiotic treatment of bacterial infections is well established. Procalcitonin (PCT) represents…
Read moreMacrophage-induced reduction of bacteriophage density limits the efficacy of pulmonary phage therapy
Thursday 16 October, 2025
Objectives: The rise of antimicrobial resistance has led to renewed interest in evaluating the efficacy of phage therapy [1]. In…
Read moreRifampin co-administration with clindamycin can result in failure to reach the PKPD targets in staphylococcal osteoarticular infections
Thursday 16 October, 2025
Objectives: In staphylococcal osteoarticular infections (OAI), the oral combination of clindamycin and rifampin, is a relevant choice [1,2]. However, rifampin…
Read moreModelling hepatitis B kinetics in mice treated by a novel TLR-7 agonist, alone or in combination with entecavir
Thursday 16 October, 2025
Objectives: Current antiviral treatment against Hepatitis B virus (HBV) rely on nucleoside analogues (such as entecavir, ETV) and are largely effective…
Read morePrediction of meropenem systemic and infection site exposure and open-loop control strategy for optimal drug dosing: a PBPK approach
Thursday 16 October, 2025
Objectives: To develop a reduced physiologically-based pharmacokinetic (PBPK) model using a retrograde approach based on a previously developed compartmental pharmacokinetic…
Read more